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Abstract
Background
Genome-wide association studies (GWAS) have considerably advanced our understand-
ing of human traits and diseases. With the increasing availability of whole genome
sequences (WGS) for pathogens, it is important to establish whether GWAS of viral
genomes could reveal important biological insights. Here we perform the first proof of con-
cept viral GWAS examining drug resistance (DR), a phenotype with well understood
genetics.
Method
We performed a GWAS of DR in a sample of 343 HIV subtype C patients failing 1st line anti-
retroviral treatment in rural KwaZulu-Natal, South Africa. The majority and minority variants
within each sequence were called using PILON, and GWAS was performed within PLINK.
HIV WGS from patients failing on different antiretroviral treatments were compared to
sequences derived from individuals naïve to the respective treatment.
Results
GWAS methodology was validated by identifying five associations on a genetic level that
led to amino acid changes known to cause DR. Further, we highlighted the ability of GWAS
to identify epistatic effects, identifying two replicable variants within amino acid 68 of the
reverse transcriptase protein previously described as potential fitness compensatory muta-
tions. A possible additional DR variant within amino acid 91 of the matrix region of the Gag
protein was associated with tenofovir failure, highlighting GWAS’s ability to identify variants
outside classical candidate genes. Our results also suggest a polygenic component to DR.
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Conclusions
These results validate the applicability of GWAS to HIV WGS data even in relative small
samples, and emphasise how high throughput sequencing can provide novel and clinically
relevant insights. Further they suggested that for viruses like HIV, population structure was
only minor concern compared to that seen in bacteria or parasite GWAS. Given the small
genome length and reduced burden for multiple testing, this makes HIV an ideal candidate
for GWAS.
Introduction
Genome-wide association studies (GWAS) have led to significant advances in the understand-
ing of complex human traits and diseases. They involve the analysis of hundreds of thousands
or millions of common genetic variants, usually single nucleotide polymorphisms (SNPs), test-
ing for an association between each variant and a phenotype (see [1]). This allows for the anal-
ysis of many variants across the genome, blind to their location or functionality. This approach
has identified hundreds of causal risk variants for dozens of diseases in the last decade (e.g. [2–
4]), each a potential drug target for novel treatments. These advances were made possible due
to the availability of cost effective SNP genotyping technologywhich capture known common
genetic variants. The limitation of this approach is that it misses variants absent from the chip,
especially rare or de novomutations. For this reason, genetic research is increasingly moving
towards whole genome sequencing approaches to capture the full range of genetic variants in a
population.
In this respect, the field of pathogen genomics is quickly catching up with human genomics,
with international collaborations currently generating thousands of whole genome sequences
(WGS) for pathogens such as HIV and malaria (e.g. the PANGEA Consortium [5] and the
MalariaGen Consortium [6]). TheseWGS allow for the application of GWAS-style identifica-
tion of novel genetic risk variants without the need for SNP genotyping chips.
A GWAS approach has previously been successfully applied to other non-virus pathogen,
almost always using treatment resistance or failure as the phenotype [7]. These studies have
included Plasmodium falciparum [8],Mycobacterium tuberculosis [9], Staphylococcus aureus
[10] and Streptococcus pneumoniae [11]. Sample sizes have ranged from 75 to 3,701 sequences,
and in even smaller samples have identified both novel and known variants that capture almost
all the variation in treatment outcome.
However, it is still unclear how well suited the viral genome is to a GWAS approach. The
only viral GWAS to date combined GWAS of human SNP and HIV amino acid data, and iden-
tifiedmultiple host genetic variants in the HLA region associated with HIV amino acid diver-
sity [12]. However they found no associations between the HIV genome and their outcome of
interest, viral load. The high percentage of coding sequence in viral genomes and overlapping
reading frames may constrain the polygenic architecture for which GWAS was conceived: with
many variants each of individually small effect. Another limitation of previous studies was that
they did not allow for heterozygosity. Heterozygosity at a locus can arise due to mixed infec-
tions or within-host pathogen genetic diversification. Although this is rare in most pathogens
studied with GWAS to date, it is highly relevant to many viral infections. Lastly, parasite and
bacterial GWAS have observed a large level of population structure presumably due in part to
homologous recombination and recent selection [13]. Given the challenges faced by previous
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analyses, more work is needed to properly define the genomic architecture of viruses and
whether it is suitable to a GWAS style approach.
To validate the effectiveness of a viral GWAS we aimed to replicate the success of bacterial
GWAS and focus on a phenotype known to be under strong selection pressure, specifically
antiretroviral therapy (ART) resistance in HIV. The provision of ART to over 6.2 million peo-
ple living with HIV in sub-Saharan Africa has been one of the most successful public health
interventions ever undertaken [14], improving life expectancy [15], and reducing transmission
[16, 17]. As a result, ART has been one of the most potent selection pressures on HIV. Given
its importance to global health, resistance to ART has beenwell studied in HIV with many
amino acid changes known to lead to DR [18]. Thus, DR is a useful phenotype for validating
GWAS in HIV as findings can be compared to the existing literature as well as to large publi-
cally available databases of genes involved in HIV DR. In this study, we aim to identify known
variants and validate the applicability of GWAS methods to the HIV genome.
Results
Genomic architecture of HIV SNPs
343 samples with phenotype and genotype data remained after variant calling and quality con-
trol (Table 1). A total of the 5379 SNPs with a minor allele frequency>= 1% were identified.
An excess of rare variants was observedwith a mean allele frequency of 11.3% and median of
6.0% (Fig A in S1 File). Additionally 2502 variants were identifiedwith a frequency less than
1% though not included in the analyses. Variants were evenly distributed across the genome,
despite missingness differing by region (Fig B in S1 File). The permuted threshold for genome-
wide significancewas p = 7E-5, less stringent than that derived by Bonferroni correction for
the number of variants (p = 9.3E-6) and suggesting that there was substantial correlation
between SNPs. This correlation is expected, due to the close proximity of SNPs inWGS data
which leads to linkage disequilibriumand the non-independence of tests. As such, genome-
wide significancewas determined using the permutation adjusted p- permutation adjusted p-
value threshold. SNPs were labelled by their base pair position plus reference allele, e.g. 1A.
SNPs were also linked to their corresponding amino acid position in the different HIV proteins
using reference sequence AF411967.
Validating GWAS with known DR variants
GWAS was performed to identify variants associated with drug resistance. The drug resistance
phenotype was binary for each drug and defined as any history, or not, of failure while treated
with the given drug. Failure was defined as at least one measure of viral load>1000 copies/ml
after 12 months of treatment. GWAS identified eight independent associations at permutation
adjusted genome-wide significance. Five of the associations were known loci involved in DR
Table 1. Number of WGS treated with each drug, and correlations between drugs within samples.
Drug Treated Untreated Correlation with:
Zidovudine Stavudine Tenofovir Efavirenz Nevirapine Lopinavir
Zidovudine 32 311 1 - - - - -
Stavudine 291 52 -0.058 1 - - - -
Tenofovir 101 242 -0.117 -0.507 1 - - -
Efavirenz 259 84 0.011 -0.023 0.128 1 - -
Nevirapine 113 230 -0.017 0.127 -0.057 -0.623 1 -
Lopinavir 26 317 0.213 -0.033 0.053 -0.151 -0.115 1
doi:10.1371/journal.pone.0163746.t001
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and all but one were in the reverse transcriptase region (RT), the functional target of these
drugs (see Table 2). Failure on tenofovir was associated with three known SNPs (2730G, 2852A
and 2880T, see Fig 1) in the RT region, at amino acid positions 65, 106, and 115, of which posi-
tion 65 and 115 were known tenofovir DR variants and position 106 was previously associated
with DR with the most common drugs used in combination with tenofovir. Treatment with
zidovudine was associated with SNP 2745G, a known drug variant in RT amino acid 70 (Fig C
in S1 File). Nevirapine treatment was associated with a SNP (3078G) at RT 181, again a previ-
ously known DR variant (Fig D in S1 File). No associations were seen with known resistance
Table 2. Results for genome-wide significant SNPs and their corresponding amino acid positions.
Drug SNP Missing-
ness
A1 Ref. Gene Amino
acid N
Ref. Amino
Acid
A1 Amino
Acid
Known OR SE Unadjusted p-
value
Permutation
adjusted p-value
Nevirapine 3078G 14% G A RT 181 Y C Yes 5.20 0.26 4.77E-10 1.00E-07
Stavudine 2739A 14% A G RT 68 S N Cis 0.08 0.54 5.38E-06 0.0081
Tenofovir 1063A 18% G A MA
(p17)
91 R G No 1.79 0.14 2.42E-05 0.016
2730G 13% G A RT 65 K R Yes 6.44 0.24 1.67E-14 1.00E-07
2738G 14% G A RT 68 S G Cis 2.89 0.24 1.45E-05 0.0088
2852A 14% A G RT 106 V M Conv. 1.72 0.14 6.19E-05 0.047
2880T 13% T A RT 115 Y F Conv. 5.77 0.41 1.80E-05 0.011
Zidovudine 2745G 16% G A RT 70 K R Yes 3.11 0.22 2.94E-07 0.0006
Note that the effect of SNP 2739A is protective against stavudine resistance (i.e. odds ratio [OR] <1) and the association is actually with tenofovir, that has a
negatively correlated prescription regime. Ref. = Reference; BP = base position; A1 = effect allele; Cis = proximal to known DR variant; Conv. = convergent,
i.e. known DR variant for another drug; OR = Odds ratio; SE = standard error.
doi:10.1371/journal.pone.0163746.t002
Fig 1. Analysis pipeline for HIV whole genome sequence (WGS) genome-wide association study
(GWAS) compared to a human study using a SNP chip. Step 1) Diploidy defined for both human and
pathogen, to reflect ‘real’ heterozygosity and heterozygosity from within host viral diversity. 2) While
missingness and Hardy-Weinberg Equilibrium are used to assess genotyping quality in human GWAS, in
viral GWAS we used depth of sequencing to assess variant calls. As such, higher calling confidence is
associated with higher missingness in viral SNPs, while the reverse is true in humans. Low minor allele
frequency (MAF) is always used to remove variants that have low power to detect effects and may reflect
errors. 3&4) Correction for ancestry and relatedness are key to human GWAS, however due to both more
homogenous sampling and difficulty in applying conventional corrections in human data to viral, this was
done as a sensitivity test in a smaller sample for top SNPs in HIV GWAS.
doi:10.1371/journal.pone.0163746.g001
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variants for lopinavir, efavirenz and stavudine (Figs E-G in S1 File). These results remained sig-
nificant after correction for confounding from population structure and length of treatment
(Table A in S1 File)
While our analyses identified several known variants for DR, not all were identified.How-
ever, it is well known in GWAS studies that sample size is a critical limitation, with additional
SNPs identifiedwhen larger samples are available. We observed a weak positive correlation in
our analyses between the number of significant associations per drug and sample size (R2 =
22%). Looking at known DRmutations [18] with data available showed an excess of significant
associations compared to expectation by chance, with 12% containing a variant at genome-
wide significance and a further 41% containing at least one at nominal significance, despite
incomplete coverage (p<0.001; Table B in S1 File). This trend was especially clear within the
primary resistance mutations.
Identification of novel variants
As well as known drug resistance variants, additional associations were observed.The first was
two associations within RT amino acid 68. The first was between tenofovir failure and SNP
2738G resulting in a change from serine to glycine. Replication was performed using the Stan-
ford University HIV Drug Resistance Database [19, 20]. Subtype C sequences within the Stan-
ford database from individuals failing to tenofovir or other NRTIs (n = 9,357) all had the
reference (serine) amino acid. For sequences showing resistance to tenofovir, however, 5.5%
had glycine at this position (n = 488, p<0.0001 compared to non exposed distribution). Stavu-
dine resistance was showed associations with a different SNP (2739A) from serine to aspara-
gine (Fig C in S1 File). However further investigation showed this to be an association with the
negatively correlated drug tenofovir which had a p-value just below genome-wide significance
for this SNP (p = 7.1E-4). This was clear both from the fact the reference sequence allele was
associated with stavudine DR, and from the results of the replication. For sequences failing on
tenofovir 4.7% had asparagine at position 68 (p<0.0001), while for sequences failing on stavu-
dine (n = 2,800) no asparagine variants were observed.While not known drug resistance vari-
ants, amino acid 68 (specifically the change to glycine) has been suggested as a compensatory
mutation for reduced fitness due to the drug resistance variant in amino acid 65 [21, 22].
Indeed epistasis was observedbetween the significant SNPs in amino acid 68 and those in
amino acids 65 and 106 (Table C in S1 File).
For tenofovir failure an association was also seen with SNP 1063A in amino acid 91 of the
matrix region, an entirely novel association (Fig 2). Whilst not available in the Stanford data-
base, we compared our results to the Los Alamos HIV SequenceDatabase drug naïve WGS at
the amino acid 91 of the matrix region. Interestingly, for the amino acid 91 we observeda high
level of genetic variation, with coding for nine amino acids. Focusing on the associated genetic
change, we observed significantly different (p<0.0001) frequencies in the drug naïve sample
(37% G vs. 61% A) compared to the tenofovir-exposed sequences in our sample (65% G vs. 35%
A). OurWGS tenofovir naïve cases had a same frequency as the publically available sequences
(37% G). While not an independent replication, this lends some support to our finding.
Population stratification and cryptic relatedness
A concern in GWAS is the possibility of confounding by population stratification, which can
lead to a systematic inflation in the number of false positives. QQ plots are a standard tool for
testing for inflation in GWAS, plotting observedp-values across the genome compared to
expected p-value distribution. These suggested a systematic deflation in p-values in this study,
with genomic lambdas between 0.66–0.80. The lambda value is derived from the median
GWAS of HIV Drug Resistance
PLOS ONE | DOI:10.1371/journal.pone.0163746 September 27, 2016 5 / 14
observed chi squared statistic divided by the median expected chi squared statistic (for p = 0.5).
Under the null distribution, a lambda of 1 is expected, with a value above 1.05–1.10 usually
taken as evidence of inflation. However, the excess of very rare variants (Fig A in S1 File) pre-
vented a normal distribution of p-values, with a reduced number of significant SNPs compared
to expected under the null. Restricting the analysis to SNPs where minor allele frequencywas
at least 10% supported this hypothesis, with an increase in genomic lambdas (0.81–1.00). To
account for this, we compared our distribution of p-values to those when the phenotype was
permuted within our data. This removed the systematic deflation in our expected vs. observed
p-value distributions (lambdas 0.99–1.36, median 1.076), now showing a distribution close to
null for the majority of SNPs (Figs H-M in S1 File). An inflation of p-values compared to per-
muted phenotypes was observedonly within the tail end of highly significant SNPs. This is a
characteristic not of population stratification but of a trait being polygenic, i.e. with many truly
causal SNPs each explaining only a small proportion of variance. This distribution is common
among human GWAS QQ plots and suggests larger studies of DR will yield additional causal
SNPs, albeit with smaller effect sizes.
Usually population stratification is addressed by correcting for ancestry informative princi-
pal components. These principal components are based on SNP correlations across the
genome, and have been shown to accurately capture population structure [23]. However their
construction proved difficult in our total sample due to much higher missingness than is typi-
cal in GWAS data from genotyping chips. As such we performed a sensitivity analysis in a
smaller sample with near complete sequencing (n = 178) to test the effect of our genome-wide
significant SNPs after correcting for principal components. No large attenuation of effect was
observed,with half of the genome-wide significant SNPs showing an increased effect size when
the first five principal components were included as covariates (Table A in S1 File). Predictably
we observedhigher p-values in the sensitivity test due to the much smaller sample size. The
partial availability of GPS data for individual’s household allowed for comparison of geo-
graphic proximity to genetic similarity (n = 34). We did not observe clear genetic clustering
overlapping with geographic (Fig 3), though a pairwise comparison of genetic distance based
on coordinates of first 2 principal components and geographic position did show a weak asso-
ciation between the two (R2 = 1.4%, p<0.005).
Another potential confounder within GWAS is relatedness between samples. Traditional
measures of human relatedness were not appropriate for the analysis of pathogen genomics
data. We performed a sensitivity test to remove samples closely linked within phylogenetic
Fig 2. Manhattan plot comparing HIV sequences that were exposed to tenofovir to those that were not. The reference line at p = 7E-5 is
the line for permutation adjusted genome wide significance. Dashed grey lines on genomic locations refer to borders of genes (black dashed
refer to GAG, Pol and ENV). Each marker is a SNP, weighted by it’s—log(p-value) to highlight the most significant SNPs.
doi:10.1371/journal.pone.0163746.g002
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clusters (N = 6). The results did not differ greatly, suggesting our top findings were not driven
by population stratification or cryptic relatedness (Table A in S1 File).
Discussion
In this study, we performed a proof of concept analysis that shows how a GWAS approach can
identifymany known variants and replicable novel associations using HIVWGS. We identified
five variants at loci which correspondedwith amino acid changes previously associated with
DR.While not all previously known DR variants were identified at genome-wide significance
in our analyses, we observed an excess of nominally significant associations at these loci
(p<0.001, Table B in S1 File). This is reminiscent of the polygenicity observed in human
GWAS. Often an excess of sub-genome-wide significant variants was identified prior to identi-
fying those specific SNPs truly associated with a trait [24]. We can expectmany of those previ-
ously known variants to become genome-wide significant once sample sizes increase.
As well as validating known variants, our results highlight two ways in which GWAS can
identify potential novel variants. The first is by identifying variants of smaller or indirect
effects, such as via epistasis. We identified two nonsynonymous variants changing the RT
amino acid 68 from a serine to asparagines or glycine. Both associations remained after correc-
tion for other treatments and potential confounders and the amino acid changes were repli-
cated in independent samples. The 68 glycine variant has been describedpreviously as
correlating with drug resistance variant at position 65 [21]. This change does not confer drug
resistance itself but rather compensates for the reduced fitness from a change at position 65
[22]. In agreement with this we observed significant interactions between the changes at posi-
tion 68 and both 65 and 106 (Table C in S1 File).
Fig 3. Plot of standardised values for the ancestry informative principle components 1 & 2 (red) and
latitude & longitude (gold) for HIV sequences, with values for each sequence linked by a line. No
correlation between geographic position and genetic position was observed.
doi:10.1371/journal.pone.0163746.g003
GWAS of HIV Drug Resistance
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The second benefit of a GWAS approach was the ability to identify novel associations out-
side of candidate regions of the genome. Here we observed a novely associated SNP outside of
the RT region of the Pol gene traditionally assumed to contain all genetic variants that provide
resistance to NNRTIs. This association with failure on tenofovir (an NNRTI) was instead
within amino acid 91 of the matrix protein of the Gag polyprotein. The effect remained after
correction for effects of other drugs, population stratification and relatedness (Table D in S1
File). This variant leads to a change in amino acid from the reference arginine to glycine, an
uncommon change though the region is highly polymorphic. In comparison to the other vari-
ants (mean odds ratio of 3.70, range 1.72–11.91), the effect size was slightly smaller at 1.78 sug-
gesting why it previously may have been unobserved.
While the current results validate the applicability of GWAS to the HIV genome, there are
some limitations. As previously mentioned, not all knownDR variants were identified at
genome-wide significance, though given many were nominally significant, this is likely to reflect
small sample size. Related to this is a bias in which types of variants were more likely to be iden-
tified in our study design. These would have related to two groups of variants. First, we would
have had greater power to detect drug resistance variants that also reduce viral fitness, meaning
they would only exist at high frequencies when directly under selection from treatment. Second,
our study design would favour identifying variants that had effects specific to one drug rather
than a class of drugs, due to most samples having been exposed to at least one drug from each
class. This was a result of the now widespread usage of ART by infected individuals and subse-
quent focus of sequencing efforts on treatment resistance. Lastly, we note that unlike bacterial
GWAS [7], we did not observe dramatic genome-wide inflation in test statistics. Our compari-
son of lambda values using permuted and unadjusted p-values suggested that Bonferroni adjust-
ment for multiple corrections is likely over conservative, while permutation adjustment may not
correct for all inflation. However, analysis of principle components suggested the genome-wide
associations were not confounded by geographic and genetic population structure.
Overall, our results provide a clear proof of concept on the use of GWAS within HIV and
other viruses whole genome sequence data. The smaller genome size, compared to humans,
means that substantially smaller samples were needed to identify associated variants. Power is
also greater because sequencing allows one to test the association with the causal variant, rather
than the proxy SNPs often used in human GWAS to capture several nearby correlated SNPs.
With a larger percentage of the genome transcribed there should also be a larger proportion of
functionally relevant variants. Additionally, viruses can themselves be used as model organisms
and can be geneticallymodified, allowing for functional validation of identified variants in a
way that cannot be performed in humans. However, these benefits of performingGWAS
within viruses should not ignore the valuable lessons from human genomics, especially the
need to quickly establish large sample sizes through internationally collaborative research (see
[25, 26]). A focus on setting up standardised quality control pipelines, making GWAS results
publically available in the form of SNP summary statistics, and pooling samples into mega-
analyses (rather than meta-analysing separate studies) should be the aim of those groups gener-
ating HIV and other virus genomes.
Methods
Sample description
The study sampled 319 HIV-infected adults and 24 children on ART with virological failure in
the Hlabisa HIV Treatment and Care Programme in South Africa for which a whole genome
of HIV-1 was produced. The inclusion criteria were: ART regimen for at least 12 months fol-
lowed by virological failure, defined as one viral load>1000 copies/ml. Exclusion criteria were:
GWAS of HIV Drug Resistance
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prior use of nucleoside reverse transcriptase inhibitor (NRTI) monotherapy or dual therapy
(not including regimens for the prevention of mother-to-child transmission (pMTCT)). All
individuals were seen by a physician, who performed a clinical evaluation and obtained written
informed consent for the study. A 5 ml EDTA whole blood sample for HIV DR genotyping
was collected during the clinical evaluation. Basic clinical and demographic data, including
GPS data on household location, were collected on a clinical form and clinical and treatment
information was compared with the records in the Africa Centre’s ART Evaluation and Moni-
toring System (ARTemis), an operational database holding treatment and laboratory monitor-
ing information from the national ART programme in South Africa. The clinical information
was entered in anonymised form into a relational sequence database, the SATuRN REGA data-
base [27]. Further details of the study have been describedpreviously [28, 29].
Ethics Statement
The study was approved by the Biomedical Research Ethics Committee of the University of Kwa-
Zulu-Natal (ref. BF052/10) and the Health Research Committee of the KwaZulu-Natal Depart-
ment of Health (ref. HRKM 176/10). South African legal guidelines define a person able to give
informed from consent from age 17. Written informed consent was obtained from all the study
participants and their parent or legal guardian in the case of paediatric patients (16 years).
Drug exposure data
The median duration of ART among patients in this cohort was 42 months (IQR 32–53). The
most common first line ART regimens were: tenofovir/stavudine/zidovudine +Lamivudine +-
efavirenz/nevirapine. The most common second line ART regimen were: Lopinavir (+ Ritona-
vir), Lamivudine, zidovudine/tenofovir. The median duration of antiretroviral failure was 27
months (IQR 17–40 months). Details on drug exposure data and DR results have been
describedpreviously [28, 29]. Drug exposure was defined by exposure at any time point prior
to sequencing. Table 1 provides a basic description of the characteristics of the 343 individuals
with viral WGS data included in the analysis.
RNA extraction, PCR amplification and whole genome sequencing
RNA was extracted from samples using the manual QIAamp Viral RNA Mini Kit (Qiagen).
The near complete HIV-1 genome was amplified by a previously describedRT-PCR strategy
with primers modified to be more subtype C specific (Danaviah et al. CROI 2015; Abstract).
The amplification involved the production of four overlapping genetic fragments of lengths of
1.9kb, 3.6kb, 3.0kb and 3.5kb. This included all nine open reading frames and partial regions of
the 5’- and 3’-LTR. The DNA concentration of individual amplicons was quantified using the
Qubit sdDNA HS Assay Kit (Thermo Fischer Scientific-LifeTechnologies). Pooled amplicons
were prepared for sequencing using the Nextera XT DNA Sample Preparation kit (Illumina)
and the Nextera XT DNA Sample Preparation Index Kit (Illumina), following the manufac-
ture’s protocol. The runs comprised pools of 96 samples that included three controls (one neg-
ative sample, one inter-run and one intra-run control). All processes to generate WGS were
undertaken locally at the Africa Centre laboratory, Nelson RMandela Medical School, Univer-
sity of KwaZulu-Natal, South Africa.
Bioinformatics pipeline
Fastq quality control was performed using FASTQC(0.11.3) and QUASR(3.1) software appli-
cations. Reads of less than 100bp in length and a quality score lower than 30 were excluded.
GWAS of HIV Drug Resistance
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In addition, the reads were trimmed up to 10bp from 5’ and 30bp at the 3’ to exclude poor
quality sequence at the beginning and end of reads. We noticed that the second pair read of
the Illumina Nextera XT was of lower quality and that excluding the last 30bp increased qual-
ity score to> 33. We imposed these exclusion criteria in order to decrease the probability of
ambiguous read mapping, which occurs when shorter reads of lower accuracy are included in
assemblies [30]. Following these quality control steps, we mapped reads against a subtype C
reference sequence (AF411967) with five assembly iterations using Geneious 8 (http://www.
geneious.com) [31]. After assembly, we exported the data as BAM files and exported contigs
as FASTA files.
In order to determine if there was clustering of sequences (i.e. sequences that were very sim-
ilar with low genetic diversity), we aligned all of the whole genomes with a reference dataset for
HIV-1 subtype C. The tree was constructedwith HKY+Gamma site rate variation in a MPI
version of RaxML. Reliability of internal nodes was evaluated by 100 bootstrap replicates. Phy-
logenies were analysed using Phylotype software application [32] in order to detect any cluster-
ing of sequences with high bootstrap values (>90%) and low sequence diversity (<3%). This
was performed to identify pairs of closely related HIV sequences that might confound the anal-
ysis and test the sensitivity of the results to their inclusion.
Variant calling and GWAS software adaptation
The processing of WGS data to the performing of GWAS is outlined in Fig 1, with comparison
to human GWAS steps. BAM files were converted to VCF format variant calls individually for
each sequence in PILON [33]. A threshold of a depth of 50 reads per base was used for a variant
to be called.
As GWAS software was originally designed for diploid organisms (i.e. those with two chro-
mosomes and so two copies of any given loci), each sample can be called either as homozygous
for an allele (e.g. AA or TT) or as heterozygous (e.g. AT). While heterozygosity is incorrect in
the sense that HIV is haploid, it captures an important reality of viral infection: genetic differ-
ences within the host’s viral population.We wanted to retain the feature of diploidy to
account for samples with diversity at a given DR loci. We expected heterozygous samples to
have an intermediate effect size compared to samples where the DR variant was either entirely
non-existent or fixed. The downside of this approach was that given numerous sequence
reads for each loci, some variation is expected due to sequencing errors. To account for this,
we allowed for diploid calling in the following manner. If the reference allele frequency was
present in>85% of reads at a loci, the loci was called as homozygous for the reference allele. A
heterozygous call with one copy of the reference variant and one of the non-reference variant
was made if the reference allele frequency was between 85% and 15% of reads. Finally, a
homozygous non-reference call was made if the reference allele frequency was found in less
than 15% of reads. While these cut-offs are simply defaults of the software, this worked as a
crude calling approach for whether an individual sample’s HIV population was fixed or mixed
for any given loci.
VCFs were then merged in GATK [34], then the combined VCF read into PLINK1.09 [35]
for GWAS analysis. Prior to analysis, several QC steps were performed. First, where multiple
alleles occurred at the same loci, the reference variant and the most common non-reference
variant were used to make the loci bi-allelic. Second, a minor allele frequency of greater than
1% was required for all variants. Lastly, we did not implement a restriction on missingness of
data. In human GWAS, highmissingness for a SNP or individual may reflect poor quality gen-
otyping. However, in HIVWGS sequencing quality is not homogenous across the genome (Fig
B in S1 File). As we had restricted analysis to calling variants at loci with a depth of 50 or
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greater, higher missingness was expected.Missingness for SNPs significantly associated with
DR is reported in Table 2.
Statistical analysis
A logistic regression was performed in PLINK1.09 [35] with drug exposure as the binary out-
come and each SNP as a predictor with an additive effect. All samples exposed to a given drug
were compared to all that were not. To determine genome-wide significancewe performed
10,000,000 permutations within PLINK1.09 both on a single SNP and genome-wide level using
the—mperm command. This was performed to account for correlation between nearby SNPs
which would have made Bonferroni correction for the raw number of statistical tests overly
conservative. Given the smaller number of variants compared to a human GWAS, permutation
using 10,000,000 for the empirical p-values was computationally feasible. As the negative corre-
lations in the prescribing of these drugs existed, associations with the same SNP were seen in
multiple analyses. However it was possible to identify when exposure was associated with the
non-reference sequence (i.e. odds ratio>1) and so, presumably, which association identified
the true drug resistant variant. Principal components were generated in GCTA [36].
Replication
Genome-wide significant SNPs within the Pol region were able to be taken forward for replica-
tion in a publically available independent sample. This was the Stanford University HIV Drug
Resistance Database [19, 20], where information on amino acid frequencies were available for
sequences exposed to different drugs. This analysis was restricted to the 13,676 subtype C
sequences. Additional analyses also made use of a subset of all publically available subtype C
WGS (n = 505) from the Los Alamos HIV SequenceDatabase (http://www.hiv.lanl.gov/). This
was done to ensure our variant frequencies were in agreement with those observed elsewhere.
Data access
Summary statistics for all SNPs of each GWAS are available online (https://figshare.com/
articles/PLOSONE_DR_GWAS_HIV/3569766). Access to the full genomes of HIV can be
done by application of a proposal to PANGEA_HIV (http://www.pangea-hiv.org/).
Supporting Information
S1 File. Supplementary Figures and Tables. Additional figures and tables for secondary anal-
yses of the data.
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